Manchester Academic Health Science Centre (MAHSC) has partnered with leading global pharmaceutical to boost clinical research, delivering greater access to new therapeutics for citizens.
The collaboration will improve the pace at which new medicines, diagnostic tools and health technology are translated into patient benefit in the area.
Also included in the alliance are the NIHR Greater Manchester Clinical Research Network and the Greater Manchester Academic Health Science Network, enabling the partnership to improve patient recruitment onto clinical trials and understand the impact of new medicines on the wider health system.
MAHSC researchers will gain early access to new drugs through the terms of the agreement, while the collaboration will also boost the training of the next generation of researchers and clinicians.
One of the key areas of focus for the partnership is biomarker research drawing on the expertise across MAHSC’s six domains: cancer, cardiovascular disease, human development, inflammation and repair, mental health and population health. Identification of new biomarkers could lead to the earlier detection of disease and the development of more effective treatments.
Roche will harness the knowledge and expertise it gains through its work in Greater Manchester to deliver innovative therapies and improved health, benefiting our local population and the wider world.